SpinChip Diagnostics
Oslo-based medtech company SpinChip Diagnostics, acquired by bioMérieux in January 2025, developed a proprietary point-of-care IVD platform using dual axle centrifugal microfluidics and disposable cartridges to deliver lab-quality high-sensitivity cardiac troponin I results within ten minutes from a blood droplet, targeting emergency departments and acute care settings.
- Company typePrivate
- Founded2012
- HeadquartersOslo, Norway
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What SpinChip Diagnostics does
SpinChip Diagnostics ASA, founded in 2012 in Oslo, Norway, developed a proprietary point-of-care (POC) in vitro diagnostics platform targeted at acute care settings where rapid laboratory-quality results drive time-critical treatment decisions. The platform combines dual axle centrifugal microfluidics with nanotechnology-based assays in single-use cartridges to deliver results from a droplet of blood in approximately ten minutes. The lead commercial assay is the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction, with additional assays in development for sepsis and other cardiovascular biomarkers. Clinical performance was validated in the APACE study, published in the Journal of the American College of Cardiology in 2024, demonstrating diagnostic accuracy comparable to established central laboratory analyzers (Roche Elecsys hs-cTnT and Abbott Architect hs-cTnI) across 3,293 plasma samples from 1,182 patients.
The platform consists of two core products: the SpinChip Analyzer (a desktop instrument integrating mechanics, mechatronics, electronics, optics, a touch display, connectivity features, embedded software, and dual complementary optical readout systems) and disposable microfluidic test cartridges containing both liquid and dried reagents in closed, contamination-free formats. The commercial model is a razor-and-blade hardware-plus-consumables proposition: instrument placement drives recurring revenue per cartridge. The primary customer use case is rapid triage of chest-pain patients in hospital emergency departments, with secondary targets in prehospital care, general practice, and remote settings. Go-to-market was planned as a phased European rollout (Nordics, BeNeLux, DACH) supported by a strategic European distribution partnership and direct hospital clinical collaborations (e.g., Basel University Hospital, Akershus University Hospital). ISO 13485:2016 certification was obtained in September 2023, a cGMP-compliant pilot cartridge production line was operating at 500–750 cartridges per day, and CE mark filing was scheduled for 2025 with commercial launch planned for H1 2026.
SpinChip was acquired by bioMérieux, a global in vitro diagnostics leader, in January 2025 for a Total Enterprise Value of EUR 138 million (NOK 1,624 million), one of the largest MedTech transactions in Norway. Prior to the full acquisition, bioMérieux had invested NOK 115 million in March 2024 as lead investor in a NOK 145 million placement, becoming the second-largest shareholder at 17–20% before completing the take-private. Historical backers included Investinor (anchor investor since 2016), Christen Sveaas (cornerstone investor, NOK 30 million in 2021), SINTEF, and MP Pensjon. SpinChip was pre-revenue at the time of acquisition; under bioMérieux ownership, the platform is being integrated as the foundation of bioMérieux's POC strategy, with planned menu expansion in acute care and global commercial rollout via bioMérieux's existing sales infrastructure.
SpinChip Diagnostics firmographics
Firmographics- Name
- SpinChip Diagnostics
- Legal name
- SpinChip Diagnostics ASA
- Website
- https://spinchip.no
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- Oslo-based medtech company SpinChip Diagnostics, acquired by bioMérieux in January 2025, developed a proprietary point-of-care IVD platform using dual axle centrifugal microfluidics and disposable cartridges to deliver lab-quality high-sensitivity cardiac troponin I results within ten minutes from a blood droplet, targeting emergency departments and acute care settings.
- Ownership category
- akta.pro rank
SpinChip Diagnostics industry classification
Industry- Product category
- Point-of-Care In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer) (HLAHAOAC)
- akta.pro secondary industry
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)
Keywords
Where SpinChip Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
SpinChip Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Point-of-Care Diagnostic Platform Sales: Sale of SpinChip Analyzer (desktop instrument) and assay-specific test cartridges. Platform is designed for scalability with ability to perform broad range of tests across therapeutic areas including cardiovascular, inflammatory/sepsis, infectious, and endocrine diseases.
- Assay/Cartridge Sales: Recurring revenue from sale of disposable test cartridges optimized for different diagnostic tests (cardiac markers like troponin I, sepsis biomarkers, etc.). Cartridges contain integrated liquid and dried reagents for specific assays.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
SpinChip Diagnostics product offering
Product offeringCore offering
SpinChip Diagnostics develops and produces an all-in-one point-of-care in vitro diagnostics platform consisting of the SpinChip Analyzer (a desktop instrument with proprietary dual axle centrifugal microfluidics and dual optical readout systems) and disposable SpinChip Test Cartridges containing integrated liquid and dried reagents. The platform delivers lab-quality diagnostic results in approximately 10 minutes from a droplet of blood at the patient's side, with the lead commercial assay being the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction.
Product overview
SpinChip Diagnostics offers an all-in-one point-of-care in vitro diagnostics platform consisting of two core products: the SpinChip Analyzer (a desktop instrument with dual axle centrifugal microfluidics and dual optical readout systems) and SpinChip Test Cartridges (disposable cartridges with integrated liquid and dried reagents). The platform delivers lab-quality diagnostic results within minutes from a droplet of blood at the point of patient care. The first commercial assay is the high-sensitivity cardiac troponin I (hs-cTnI) test for acute myocardial infarction diagnosis, with additional assays in development for sepsis and other cardiovascular biomarkers.
Differentiator
Problem solved
Functional benefit
Products and services
- SpinChip Analyzer A desktop point-of-care analyzer that processes disposable SpinChip Test Cartridges. It includes mechanics, mechatronics, electronics, optics, a user touch interface, connectivity features, and embedded software. It features a unique dual axle centrifugal system that enables automated cartridge processing, and dual complementary optical readout systems for result generation and communication. Built for hospitals, emergency departments, urgent care units, and other acute care settings that need lab-quality diagnostic results in minutes.
- SpinChip Test Cartridge Disposable microfluidic test cartridge that holds both liquid and dried reagents. It processes samples and reagents according to specific assaying and readout principles using centrifugal force for liquid handling, including reagent dissolution, mixing, splitting, exact metering, dispensing, and flow through filters. Designed for use with the SpinChip Analyzer across multiple assay types (cardiac, sepsis, inflammatory, infectious, endocrine).
- High-Sensitivity Cardiac Troponin I (hs-cTnI) Test A high-sensitivity immunoassay for early detection of acute myocardial infarction (heart attack), run on the SpinChip Analyzer and Cartridge platform. Demonstrated diagnostic performance comparable to central laboratory assays (Roche Elecsys hs-cTnT, Abbott Architect hs-cTnI) in the APACE clinical study published in JACC, with results delivered in approximately 10 minutes from a droplet of blood. Targeted at hospital emergency departments, urgent care units, and acute care settings.
Quantifiable outcome
- SpinChip hs-cTnI POC test demonstrated diagnostic accuracy comparable to Roche Elecsys hs-cTnT and Abbott Architect hs-cTnI laboratory assays in APACE study with 3,293 plasma samples from 1,182 patients
- +3 more outcomes
Companies that use SpinChip Diagnostics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
SpinChip Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
SpinChip Diagnostics partnerships and signals
Strategic signalScale indicators10 records
Recent moves7 records
Expansion highlights6 records
SpinChip Diagnostics competitors and assessment
Company assessmentDirect peers
- QuidelOrtho (Triage): QuidelOrtho's Triage MeterPro and TriageTrue platforms deliver POC cardiac biomarkers (Troponin I, BNP, D-dimer) in emergency and acute care settings. Directly comparable to SpinChip as a same-vertical cardiac POC immunoassay platform with razor/blade cartridge economics.
- Abbott Point of Care (i-STAT): Abbott's i-STAT system is one of the most widely deployed POC platforms globally, with a hs-cTnI cartridge directly competing against SpinChip's troponin assay in emergency departments. Same target customer (hospital EDs), same assay category, same business model of analyzer + disposable cartridge.
- Siemens Healthineers (Atellica VTLI): Siemens' Atellica VTLI is a POC immunoassay system with a cardiac menu including high-sensitivity troponin I, designed for emergency and acute-care use. Direct competitor to SpinChip on assay menu, performance claims, and customer base.
- Radiometer (Danaher) — AQT90 FLEX: Radiometer's AQT90 FLEX is a POC immunoassay analyzer used in emergency departments for cardiac markers including troponin. Direct peer in target customer (hospital EDs/acute care), assay category, and POC platform economics; Radiometer is a Danaher-owned incumbent.
- Response Biomedical (RAMP): Response Biomedical's RAMP platform is a POC cardiovascular testing system with troponin I assays marketed to emergency departments and acute care. Directly comparable niche player targeting the same cardiac POC opportunity as SpinChip.
- Trinity Biotech (Meridian branded POC): Trinity Biotech offers POC cardiac biomarker tests including troponin I on its Meritas and related platforms. A specialty IVD peer in the same cardiac POC segment as SpinChip, targeting hospital labs and acute care settings.
Emerging players
- Boditech Med: South Korea-based Boditech Med develops POC immunoassay platforms (ichroma series) with cardiac panels including troponin I. Comparable as an emerging POC player in cardiac diagnostics with a similar cartridge-based architecture, though stronger in Asian markets than Europe.
- EKF Diagnostics (QuikRead): EKF Diagnostics' QuikRead and related POC products include CRP and other acute-care biomarkers; smaller-scale POC peer targeting similar primary care and acute care customers. Comparable in business model (analyzer + disposable) though with a different assay focus than SpinChip's cardiac-first menu.
Broad incumbents
- bioMérieux (VIDAS): bioMérieux's VIDAS franchise is a broad immunoassay menu including cardiac biomarkers, and bioMérieux is now SpinChip's parent company. A broader IVD incumbent whose VIDAS platform overlaps SpinChip's roadmap and whose global distribution is now the primary commercialization channel for SpinChip.
- Roche Diagnostics (cobas Liat): Roche's cobas Liat is a rapid POC molecular PCR system used in urgent care and EDs; Roche Elecsys hs-cTnT is the central-lab benchmark SpinChip matched in the APACE study. Broader IVD incumbent whose lab assay is the direct competitor SpinChip displaces at the POC.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
SpinChip Diagnostics social profiles
Digital presenceSpinChip Diagnostics compliance and trust
Trust signalCompliance1 record
SpinChip Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
SpinChip Diagnostics leadership team
Management profileNumber of profiles
Profiles10 records
SpinChip Diagnostics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SpinChip Diagnostics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SpinChip Diagnostics
What does SpinChip Diagnostics do?
SpinChip Diagnostics develops and produces an all-in-one point-of-care in vitro diagnostics platform consisting of the SpinChip Analyzer (a desktop instrument with proprietary dual axle centrifugal microfluidics and dual optical readout systems) and disposable SpinChip Test Cartridges containing integrated liquid and dried reagents. The platform delivers lab-quality diagnostic results in approximately 10 minutes from a droplet of blood at the patient's side, with the lead commercial assay being the high-sensitivity cardiac troponin I (hs-cTnI) test for early diagnosis of acute myocardial infarction.
Is SpinChip Diagnostics a public or private company?
SpinChip Diagnostics is a private company. It is classified as corporate owned and is currently acquired.
When was SpinChip Diagnostics founded?
SpinChip Diagnostics was founded in 2012. It employs 11 to 50 people.
Where is SpinChip Diagnostics based?
SpinChip Diagnostics is headquartered in Oslo, Norway, in the Europe region.
How does SpinChip Diagnostics make money?
Two revenue lines are on record. Point-of-Care Diagnostic Platform Sales are the primary driver. The others are assay/Cartridge Sales.
Who are SpinChip Diagnostics's main competitors?
Direct peers on record are QuidelOrtho (Triage), Abbott Point of Care (i-STAT), Siemens Healthineers (Atellica VTLI), Radiometer (Danaher) — AQT90 FLEX, Response Biomedical (RAMP) and Trinity Biotech (Meridian branded POC). Emerging players are Boditech Med and EKF Diagnostics (QuikRead). Broad incumbents are bioMérieux (VIDAS) and Roche Diagnostics (cobas Liat).
Does SpinChip Diagnostics have an API?
No public API is recorded for SpinChip Diagnostics.
What industry is SpinChip Diagnostics in?
SpinChip Diagnostics's product category is Point-of-Care In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAOAC, Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer), with a secondary code of HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 325413 and its SIC code is 2835.